| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Smoothelin; SMTN; SMSMO |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | A synthetic peptide corresponding to a sequence at the N-terminus of human Smoothelin, which shares 97.3% amino acid (aa) sequence identity with mouse Smoothelin. |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
This antibody is intended for detection of SMTN (Vesicular acetylcholine transporter) in biological samples using common immunoassay formats. It is typically selected based on target identity, species reactivity, clonality/clone information, and detection modality.
Vendor notes: Boster Bio Anti-Smoothelin/SMTN Antibody Picoband® catalog # A04895. Tested in WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
Key elements and design rationale
- Antibody format: Rabbit Polyclonal Rabbit IgG
- Immunogen / epitope context: A synthetic peptide corresponding to a sequence at the N-terminus of human Smoothelin, which shares 97.3% amino acid (aa) sequence identity with mouse Smoothelin.
- Molecular weight context: reported MW: 120 kDa; calculated MW: 56903 MW
- Reactivity: Human
- Applications: WB
As a polyclonal antibody, the reagent recognizes multiple epitopes on the target, which can improve detection robustness but may increase sensitivity to sample-dependent epitope changes.
Biological background
Vesicular acetylcholine transporter; smoothelin. Smoothelin is a protein that in humans is encoded by the SMTN gene. This gene encodes a structural protein that is found exclusively in contractile smooth muscle cells. It associates with stress fibers and constitutes part of the cytoskeleton. This gene is localized to chromosome 22q12.3, distal to the TUPLE1 locus and outside the DiGeorge syndrome deletion. Alternative splicing of this gene results in multiple transcript variants encoding distinct isoforms. Functional note: Structural protein of the cytoskeleton. Reported localization: Cytoplasm, cytoskeleton. Exhibits a filamentous organization. Expression/tissue context: Smooth muscle; contractile or vascular (for the long form).
Research relevance and current trends
- Vasculature: Researchers commonly examine how SMTN (Vesicular acetylcholine transporter) relates to this theme using model systems and orthogonal readouts.
Common research applications
- Western blotting: compare relative SMTN (Vesicular acetylcholine transporter) levels across conditions; band patterns may reflect isoforms and processing.
Notes for experimental interpretation
- Specificity notes: No cross reactivity with other proteins.
- Cross-reactivity: No cross-reactivity with other proteins.
- Isoforms and PTMs: Apparent size and signal patterns can differ across splice isoforms, proteolytic processing, and post-translational modifications.
- Controls: Include an isotype control (as relevant), no-primary control for imaging, and orthogonal validation such as KD/KO samples when available.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
